A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

The curious minds at ColdFusion break down CAR-T therapy designed to target and kill cancer cells.

Blood Cancer UK, Lymphoma Action and stem cell charity Anthony Nolan have formally appealed against the decision.

Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

Scientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumor’s own defenses against ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular ...

Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

US FDA grants orphan drug designation to Imviva Biotech’s CTD402 for the treatment of T-cell leukaemia and lymphoma: Boston Friday, January 30, 2026, 17:00 Hrs [IST] Imviva Biot ...